Viatris Inc

Viatris is a global healthcare company that empowers people worldwide to live healthier at every stage of life. The company was formed through the combination of Upjohn, a global, primarily off-patent branded and generic established medicines business, and Mylan, a leading manufacturer of generic drugs. Viatris' mission is to bridge the traditional divide between generics and brands and provide access to high-quality medicines at scale. The company's business model is designed to deliver on its strategy of providing access to medicines, focusing on leadership and partnership. Viatris operates in three core, global therapeutic areas: ophthalmology, gastrointestinal, and dermatology. The company covers a broad range of therapeutic areas and helps ease the burden of noncommunicable diseases, particularly cardiovascular diseases and infectious diseases such as HIV/AIDS. Viatris has a strong pipeline of both generic and innovative products, including potential first-to-market generics and complex products. The company's website is [www.viatris.com](http://www.viatris.com), and its stock is traded on the NASDAQ under the ticker symbol VTRS. Viatris is committed to advancing sustainable operations and innovative solutions to improve patient health and support more resilient healthcare systems. The company's global operating platform combines best-in-class manufacturing and supply chain capabilities to be a reliable and flexible partner for access across the world. As of December 31, 2023, Viatris operated approximately 40 manufacturing sites worldwide.